New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin NK2 Receptor Antagonists
作者:Paul W. Smith、Anthony W. J. Cooper、Richard Bell、Isabel J. M. Beresford、Paul M. Gore、Andrew B. McElroy、John M. Pritchard、Victoria Saez、Neil R. Taylor
DOI:10.1021/jm00019a006
日期:1995.9
loss in binding affinity. Compound 3a was shown to be a potent NK2 receptor antagonist in guinea pig trachea where it also demonstrated 1000-fold selectivity for NK2 receptors over NK1. In the anesthetized guinea pig, compound 3a administered by the intravenous or oral route displayed potent and long-lasting antagonist activity against NK2 receptor agonist induced bronchoconstriction.
描述了一系列2-(5-氟-1H-吲哚-3-基)乙基螺哌啶的合成及其在大鼠结肠结合试验中测得的速激肽NK2受体亲和力。观察到对螺恶唑烷酮3-苄基-8- [2-(5-氟-1H-吲哚-3-基)乙基] -1-氧杂-3,8-二氮杂螺[4.5] decan-2的等效NK2受体结合亲和力-1(3a),咪唑啉酮3-苄基-8- [2-(5-氟-1H-吲哚-3-基)乙基] -1,3,8-三氮杂螺[4.5] decan-2-one(3s ),和吡咯烷酮2-苄基-8- [2-(5-氟-1H-吲哚-3-基)乙基] -2,8-二氮杂螺[4.5] decan -3-一(3t)。化合物3a的苯环中的取代在NK2结合亲和力上没有产生明显的增强。用其他芳环取代3a中的苯环会导致结合亲和力显着下降。在豚鼠气管中,化合物3a被证明是有效的NK2受体拮抗剂,与NK1相比,它对NK2受体的选择性也高出1000倍。在麻醉的豚鼠中,通过